ENDRA Life Sciences (NASDAQ:NDRA – Get Free Report) is projected to issue its Q1 2025 quarterly earnings data before the market opens on Tuesday, May 13th. Analysts expect ENDRA Life Sciences to post earnings of ($4.08) per share for the quarter.
ENDRA Life Sciences (NASDAQ:NDRA – Get Free Report) last announced its earnings results on Monday, March 31st. The company reported ($9.40) EPS for the quarter, missing the consensus estimate of ($4.10) by ($5.30). On average, analysts expect ENDRA Life Sciences to post $-47 EPS for the current fiscal year and $-15 EPS for the next fiscal year.
ENDRA Life Sciences Stock Performance
Shares of NDRA stock opened at $3.26 on Monday. The company has a market capitalization of $1.83 million, a P/E ratio of 0.00 and a beta of 0.19. The company’s 50 day moving average price is $4.27 and its two-hundred day moving average price is $5.21. ENDRA Life Sciences has a 52 week low of $2.90 and a 52 week high of $602.00.
Wall Street Analysts Forecast Growth
Read Our Latest Stock Analysis on ENDRA Life Sciences
ENDRA Life Sciences Company Profile
ENDRA Life Sciences Inc develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion.
Read More
- Five stocks we like better than ENDRA Life Sciences
- Options Trading – Understanding Strike Price
- Constellation Powers Up With Reinforced AI Data Center Strategy
- How to Use the MarketBeat Stock Screener
- Top Analyst-Rated Healthcare Stocks to Watch Now
- What to Know About Investing in Penny Stocks
- GlobalFoundries Stock Hits Bottom: Is a Rebound Coming?
Receive News & Ratings for ENDRA Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ENDRA Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.